One approach for the enhancement of oral drug bioavailability is the technique of nanoparticle preparation. Risedronate sodium (Biopharmaceutical Classification System Class III) was chosen as a model compound with high water solubility and low intestinal permeability. Eighteen samples of risedronate sodium were prepared by the solvent evaporation technique with sodium dodecyl sulfate, polysorbate, macrogol, sodium carboxymethyl cellulose and sodium carboxymethyl dextran as nanoparticle stabilizers applied in three concentrations. The prepared samples were characterized by dynamic light scattering and scanning electron microscopy. Fourier transform mid-infrared spectroscopy was used for verification of the composition of the samples. The particle size of sixteen samples was less than 200 nm. Polysorbate, sodium carboxymethyl dextran and macrogol were determined as the most favourable excipients; the particle size of the samples of risedronate with these excipients ranged from 2.8 to 10.5 nm.

Department of Chemical Drugs Faculty of Pharmacy University of Veterinary and Pharmaceutical Sciences Palackeho 1 3 Brno 61242 Czech Republic

Department of Chemical Theory of Drugs Faculty of Pharmacy Comenius University Kalinciakova 8 Bratislava 83232 Slovakia

Nanotechnology Centre VSB Technical University of Ostrava 17 listopadu 15 2172 Ostrava 70833 Czech Republic

Zobrazit více v PubMed

Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods. 2000;44:239–245. PubMed

Lipinski C.A., Lombardo F. Experimental and computational approaches to estimated solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001;46:3–26. PubMed

Kerns E.H., Li D. Drug-Like Properties: Concept, Structure Design and Methods. Elsevier; San Diego, CA, USA: 2008.

Sivasankar M., Kumar B.P. Role of nanoparticles in drug delivery system. Int. J. Res. Pharm. Biol. Sci. 2010;1:41–66.

Shaikh M.S., Nikita D. Permeability enhancement techniques for poorly permeable drugs: A review. J. Appl. Pharm. Sci. 2012;2:34–39.

Onoue S., Yamada S., Chan H.K. Nanodrugs: Pharmacokinetics and safety. Int. J. Nanomed. 2014;9:1025–1037. PubMed PMC

Nehoff H., Parayath N.N., Domanovitch L., Taurin S., Greish K. Nanomedicine for drug targeting: Strategies beyond the enhanced permeability and retention effect. Int. J. Nanomed. 2014;9:2539–2555. PubMed PMC

Delie F., Blanco-Prieto M.J. Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules. 2005;10:65–80. PubMed PMC

Konan Y.N., Berton M., Gurny R., Allemand E. Enhanced photodynamic activity of meso-tetra(4-hydroxyphenyl)porphyrin by incorporation into sub-200 nm nanoparticles. Eur. J. Pharm. Sci. 2003;18:241–249. PubMed

Bawa R. Nanoparticle-based therapeutics in humans: A survey. Nanotechnol. Law Bus. 2008;5:135–155.

Bawa R. Nanopharmaceuticals for drug delivery–A review. Drug Deliv. 2009;3:122–127.

Ezra A., Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv. Drug Del. Rev. 2000;42:175–195. PubMed

Aft R., Perez J.R., Raje N., Hirsh V., Saad F. Could targeting bone delay cancer progression? Potential mechanisms of action of bisphosphonates. Crit. Rev. Oncol. Hematol. 2012;82:233–248. PubMed

Van Beek E.R., Lowik C.W., Ebetino F.H., Papapoulos S.E. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: Structure-activity relationships. Bone. 1998;23:437–442. PubMed

MedicineNet. [(accessed on 5 August 2014)]. Available online: http://www.medicinenet.com/risedronate/article.htm.

eMedTV–Health Information Brought to Life™. [(accessed on 5 August 2014)]. Available online: http://osteoporosis.emedtv.com/

Risedronate: Drug Bank Online–drugbank.ca. [(accessed on 5 August 2014)]. Available online: http://www.drugbank.ca/drugs/DB00884.

Mitchel D.Y., Barr W.H., Eusebio R.A., Stevens K.A., Duke F.P., Rusell D.A., Nesbitt J.D., Powell J.A., Thompson G.A. Risedronate pharmacokinetics intra- and inter-subject variability upon single-dose intravenous and oral administration. Pharm. Res. 2001;18:166–170. PubMed

Dissette V., Bozzi P., Bignozzi C.A., Dalpiaz A., Ferraro L., Beggiato S., Leo E., Vighi E., Pasti L. Particulate adducts based on sodium risedronate and titanium dioxide for the bioavailability enhancement of oral administered bisphosphonates. Eur. J. Pharm. Sci. 2010;41:328–336. PubMed

Oktabec Z., Kos J., Mandelova Z., Havelkova L., Pekarek T., Rezacova A., Placek L., Tkadlecova M., Havlicek J., Dohnal J., et al. Preparation and properties of new co-crystals of ibandronate with gluco- or galactopyranoside derivatives. Molecules. 2010;15:8973–8987. PubMed PMC

Kos J., Pentakova M., Oktabec Z., Krejcik L., Harokova P., Hruskova J., Pekarek T., Dammer O., Havlicek J., Kral V., et al. Crystallization products of risedronate with carbohydrates and their substituted derivatives. Molecules. 2011;16:3740–3760. PubMed PMC

Jung I.W., Han H.K. Effective mucoadhesive liposomal delivery system for risedronate: Preparation and in vitro/in vivo characterization. Int. J. Nanomed. 2014;9:2299–2306. PubMed PMC

Vaculikova E., Grunwaldova V., Kral V., Dohnal J., Jampilek J. Primary investigation of the preparation of nanoparticles by precipitation. Molecules. 2012;17:11067–11078. PubMed PMC

Vaculikova E., Grunwaldova V., Kral V., Dohnal J., Jampilek J. Preparation of candesartan and atorvastatin nanoparticles by solvent evaporation. Molecules. 2012;17:13221–13234. PubMed PMC

Vaculikova E., Placha D., Cech-Barabaszova K., Jampilek J. Cimetidine nanoparticles study. Adv. Sci. Eng. Med. 2014;6:477–481.

Thorat A.A., Dalvi S.V. Liquid antisolvent precipitation and stabilization of nanoparticles of poorly water soluble drugs in aqueous suspensions: Recent developments and future perspective. Chem. Eng. J. 2012;181/182:1–34.

U.S. Food and Drug Administration–Generally Recognized as Safe (GRAS) [(accessed on 5 August 2014)]; Available online: http://www.fda.gov/food/IngredientspackagingLabeling/GRAS/

Merkus H.G. Particle Size Measurements: Fundamentals, Practice, Quality. Springer Science+Business Media B.V.; Dordrecht, The Netherlands: 2009.

Win K.Y., Feng S.S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26:2713–2722. PubMed

Malvern Instruments Ltd: Dynamic Light Scattering Common Terms Defined. [(accessed on 5 August 2014)]. Available online: http://www.biophysics.bioc.cam.ac.uk/wp-content/uploads/2011/02/DLS_Terms_defined_Malvern.pdf.

Advances in Use of Nanomaterials for Musculoskeletal Regeneration

Preparation of Hydrochlorothiazide Nanoparticles for Solubility Enhancement